BridgeBio Pharma, Inc.
If you purchased BridgeBio Pharma, Inc. securities and would like to join the action, please click "Join This Action" below.
BRIDGEBIO MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE MERGER OF BRIDGEBIO PHARMA, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – BBIO
December 3, 2020.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of BridgeBio Pharma, Inc. (NASDAQ: BBIO) and Eidos Therapeutics, Inc. is fair to BridgeBio shareholders.
Under the merger agreement, Eidos stockholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash for each share of Eidos common stock owned. In connection with the merger, BridgeBio will seek to issue more BridgeBio shares which need to be approved by the affirmative vote of a majority of the votes cast by BridgeBio’s stockholders voting on such matter.
The investigation concerns whether BridgeBio and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for BridgeBio shareholders; and (2) disclose all material information necessary for BridgeBio shareholders to adequately assess and value the merger consideration.
On behalf of BridgeBio shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.